Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor

Tvardi Therapeutics has announced that the first patients have been dosed in each arm of its REVERT LIVER CANCER trial, which is evaluating TTI-101 as monotherapy and in combination with standard of care therapy for liver cancer. The trial is designed to evaluate TTI-101 across multiple lines of therapy and is currently enrolling HCC patients at top US cancer research institutes. Liver cancer is..